Division of Translational Cancer Research, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK); Translational Cancer Research and Institute of Experimental Cancer Therapy, Klinikum rechts der Isar, School of Medicine, Technical University of Munich; Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich.
Division of Translational Cancer Research, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK); Translational Cancer Research and Institute of Experimental Cancer Therapy, Klinikum rechts der Isar, School of Medicine, Technical University of Munich; Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich; Department of Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich;
J Vis Exp. 2022 Oct 4(188). doi: 10.3791/64253.
Pancreatic ductal adenocarcinoma (PDAC) is a very complex disease characterized by a heterogeneous tumor microenvironment made up of a diverse stroma, immune cells, vessels, nerves, and extracellular matrix components. Over the years, different mouse models of PDAC have been developed to address the challenges posed by its progression, metastatic potential, and phenotypic heterogeneity. Immunocompetent mouse orthotopic allografts of PDAC have shown good promise owing to their fast and reproducible tumor progression in comparison to genetically engineered mouse models. Moreover, combined with their ability to mimic the biological features observed in autochthonous PDAC, cell line-based orthotopic allograft mouse models enable large-scale in vivo experiments. Thus, these models are widely used in preclinical studies for rapid genotype-phenotype and drug-response analyses. The aim of this protocol is to provide a reproducible and robust approach to successfully inject primary mouse PDAC cell cultures into the pancreas of syngeneic recipient mice. In addition to the technical details, important information is given that must be considered before performing these experiments.
胰腺导管腺癌 (PDAC) 是一种非常复杂的疾病,其特征是肿瘤微环境具有异质性,由多种基质、免疫细胞、血管、神经和细胞外基质成分组成。多年来,已经开发出不同的 PDAC 小鼠模型,以应对其进展、转移潜力和表型异质性带来的挑战。与基因工程小鼠模型相比,PDAC 的免疫活性同种异体原位移植具有快速且可重现的肿瘤进展,因此具有很好的应用前景。此外,基于细胞系的原位移植小鼠模型能够模拟自发 PDAC 中的生物学特征,结合其在体内进行大规模实验的能力,因此被广泛应用于临床前研究,用于快速进行基因型-表型和药物反应分析。本方案旨在提供一种可重复且稳健的方法,成功地将原代小鼠 PDAC 细胞培养物注射到同种异体受体小鼠的胰腺中。除了技术细节之外,在进行这些实验之前,还提供了必须考虑的重要信息。